Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents

Journal of Hypertension

Volumn 26, Issue 8, 2008, Pages 1590-1594

  Santoro, Nicola ^a   Del Giudice, Emanuele Miraglia ^a,c   Grandone, Anna ^a   Marzuillo, Pierluigi ^a   Cozzolino, Domenico ^b   Di Salvo, Giovanni ^c   Pacileo, Giuseppe ^c   Calabrò, Raffaele ^c   Perrone, Laura ^a  

^a Department of Pediatrics ^*  (Italy)

^b Cardiovascular Research Center   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Blood pressure; Obesity; Polymorphisms; PYY; Y2R

Indexed keywords

NEUROPEPTIDE RECEPTOR; PEPTIDE YY; UNCLASSIFIED DRUG; Y2 RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR;

ADOLESCENT; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC VARIABILITY; GROUPS BY AGE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; PHENOTYPE; RISK FACTOR; STATISTICAL MODEL;

ADOLESCENT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHILD; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; OBESITY; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, NEUROPEPTIDE Y; RISK FACTORS; VARIATION (GENETICS);

EID: 51549104158     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830413ed     Document Type: Article

References (24)

1. Sokol RJ. The chronic disease of childhood obesity: the sleeping giant has awakened [editorial]. J Pediatr 2000; 136:711-713.
2. Whincup PH, Cook DG, Geleijnse JM. A life course approach to blood pressure. In: Kuh D, Ben-Shomo Y, editors. A life course approach to chronic disease epidemiology. Oxford: Oxford University Press; 2004. pp. 218-239.
3. McGill HC Jr, McMahan CA. Starting earlier to prevent heart disease. JAMA 2003; 290:2320-2322.
4. Abounader R, Villemure JG, Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1. antagonist BIBP3226. Br J Pharmacol 1995; 116:2245-2250.
5. Prieto D, Simonsen U, Nyborg NC. Regional involvement of an endothelium-derived contractile factor in the vasoactive actions of neuropeptide Y in bovine isolated retinal arteries. Br J Pharmacol 1995; 116:2729-2737.
6. Malmstrom RE. Neuropeptide Y Y1. receptor mechanisms in sympathetic vascular control. Acta Physiol Scand Suppl 1997; 636:1. -55.
7. Malstrom RE, Lundberg JON, Weitzberg E. Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y2. receptor evidenced by BIIE0246. Eur J Pharmacol 2002; 439:113-119.
8. Gradin KA, Buus CL, Li JY, Frobert O, Simonsen U. Neuropeptide Y2. receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats. Br J Pharmacol 2006; 148:703-713.
9. Pedersen-Bjergaard U, Host U, Kelbaek H, Schifter S, Rehfeld JF, Faber J, Christensen NJ. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin 1996; 56:497-503.
10. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release ofa putative new gut hormone, peptide YY. Gastroenterology1985; 89:1070-1077.
11. Gandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36. and PYY 3-36. Regul Pept 1994; 51:151-159.
12. Martin JR. Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by nonadrenergic, noncholinergic mechanisms. Auton AutacoidPharmacol2005; 25:53-67.
13. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51:170-179.
14. Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A. Variation of the Wt/Hr2. index from birth to 87. years. Eur J Clin Nutr 1991; 45:13-21.
15. Wuhl E, Witte K, Soergel M, Mehls O, Schaefer F, German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002; 20:1995-2007.
16. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J. Common neuropeptide Y2. receptor gene variant is protective against obesity among Swedish men. Int J Obes Relat Metab Disord 2006; 30:453-459.
17. Hung CCC, Pirie F, Luan J, Lank E, Motola A, Yeo GSH, et al. Studies of the peptide YY and neuropeptide Y2. receptor genes in relation to human obesity and obesity related traits. Diabetes 2004; 53:2461-2466.
18. Ma L, Tataranni PA, Hanson RL, Infante AM, Kobes S, Bogardus C, Baier LJ. Variations in peptide YY and Y2. receptor genes are associated with severe obesity in Pima Indian men. Diabetes 2005; 54:1598. -1602.
19. Miraglia del Giudice E, Santoro N, Cirillo G, Raimondo P, Grandone A, D'Aniello A, et al. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obes Relat Metab Disord 2004; 28:447. -450.
20. Fried G, Terenius L, Dockray G, Farhenkrug J, Goldstein M, Hokfelt T. Neuropeptide Y and noradrenaline coexist in sympathetic neurons innervating the bovine spleen. Cell Tissue Res 1986; 243:495-508.
21. Michalkiewicz M, Knestaut KM, Bytchkova EY, Michalkiewicz T. Hypotension and reduced catecholamines in neuropeptide Y transgenic rats. Hypertension 2003; 41. :1056-1062.
22. Malstrom RE. Pharmacology ofneuropeptide Y receptor antagonists focus on cardiovascular functions. Eur J Pharmacol 2002; 447:11. -30.
23. Coelho EF, Ferrari MFR, Maximino JR, Fior-Chadi DR. Change in the expression of NPY receptors subtypes Y1. and Y2. in central and peripheral neurons related to the control of blood pressure in rats following experimental hypertension. Neuropeptides 2004; 38:77. -82.
24. Aguirre JA, Hedlund PB, Narváez JA, Bunnemann B, Ganten D, Fuxe K. Increased vasopressor actions of intraventricular neuropeptide Y-(13-36) in spontaneously hypertensive versus normotensive Wistar-Kyoto rats. Possible relationship to increases in Y2. receptor binding in the nucleus tractus solitarius. Brain Res 1995; 684:159-164.